Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.